Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
argenx SE - American Depositary Shares
(NQ:
ARGX
)
755.42
+7.17 (+0.96%)
Streaming Delayed Price
Updated: 12:40 PM EDT, Apr 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about argenx SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
↗
March 21, 2026
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
↗
March 21, 2026
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
Via
The Motley Fool
Topics
Regulatory Compliance
argenx announces Annual General Meeting of Shareholders on May 6, 2026
March 20, 2026
From
argenx SE
Via
GlobeNewswire
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund
↗
March 20, 2026
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
Via
The Motley Fool
Topics
Regulatory Compliance
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
March 12, 2026
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal...
Via
Finterra
Topics
Economy
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch
↗
March 09, 2026
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of...
Via
Stocktwits
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
March 06, 2026
From
argenx SE
Via
GlobeNewswire
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
February 26, 2026
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"...
Via
Finterra
Topics
Earnings
Economy
Intellectual Property
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
February 26, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at TD Cowen 46th Annual Healthcare Conference
February 23, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
February 19, 2026
From
argenx SE
Via
GlobeNewswire
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash
↗
February 17, 2026
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Via
The Motley Fool
Topics
Regulatory Compliance
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million
↗
February 17, 2026
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Via
The Motley Fool
Topics
Regulatory Compliance
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake
↗
February 17, 2026
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Via
The Motley Fool
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More
↗
February 17, 2026
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Via
The Motley Fool
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
February 06, 2026
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a...
Via
Finterra
Topics
ETFs
Economy
Initial Public Offering
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026
From
argenx SE
Via
GlobeNewswire
argenx Highlights 2026 Strategic Priorities
January 12, 2026
From
argenx SE
Via
GlobeNewswire
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
January 06, 2026
From
argenx SE
Via
GlobeNewswire
argenx Announces Leadership Transition Marking Next Evolution of Growth
January 05, 2026
From
argenx SE
Via
GlobeNewswire
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
January 02, 2026
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
December 31, 2025
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
December 26, 2025
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine...
Via
PredictStreet
Topics
Economy
Intellectual Property
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
December 15, 2025
From
argenx SE
Via
GlobeNewswire
ARGENX SE (NASDAQ:ARGX) Combines Minervini Trend Strength with Explosive Fundamental Growth
↗
December 01, 2025
ARGENX (ARGX) stock combines strong technical trends with explosive fundamental growth in EPS and sales, making it a high-momentum candidate for investors.
Via
Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
↗
November 19, 2025
Via
Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
↗
November 18, 2025
Via
Benzinga
argenx Announces Results of Extraordinary General Meeting of Shareholders
November 18, 2025
From
argenx SE
Via
GlobeNewswire
Argenx SE - ADR (NASDAQ:ARGX) Fits Navellier's 'Little Book' Growth Rules
↗
November 14, 2025
Argenx SE fits a proven growth stock strategy, showing explosive earnings and sales growth, widening margins, and strong cash flow.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
